LegoChem licenses out ADC technology... a KRW 2.2 tril deal
By Son, Hyung-Min | translator Kim, Jung-Ju
23.12.26 12:23:25
가나다라
0
LegoChem Biosciences successfully exports its ADC 'LCB84' technology to Janssen on June 26...'the largest upfront payment and contract size this year
Only Trodelvy is available for TROP2 ADC commercialization …Daiichi Sankyo is developing datopotamab
LegoChem Biosciences' TROP2 targeted antibody-drug conjugate technology has been licensed out to Janssen. By signing a total of 13 technology transfer and option agreements in the field of ADC alone this year.
According to industry sources, LegoChem Biosciences signed a technology transfer agreement with Janssen on the 26th for its TROP2 targeted new ADC drug candidate.
#1 The contract is valued at USD 1.7 billion (approx KRW 224). It includes an upfront payment of $100 million (approx 260 billion) an exclusive development rights payment of $200 million and tiered milestones based on development, licensing, and commercialization. Royalties based on net sales will be earned separately.
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)